Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis-Reference-Cited by-同舟云学术

Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma—Polish Lymphoma Research Group real-life analysis

Published:2019-06 Issue:3 Volume:71 Page:473-477
ISSN:1734-1140
Container-title:Pharmacological Reports
language:en
Short-container-title:Pharmacological Reports

Author:

Długosz-Danecka Monika,Hus Iwona,Puła Bartosz,Jurczyszyn Artur,Chojnacki Tomasz,Blajer-Olszewska Beata,Drozd-Sokołowska Joanna,Raźny Małgorzata,Romejko-Jarosińska Joanna,Taszner Michał,Jurczak Wojciech

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,General Medicine

Reference30 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia;Sehn;J Clin Oncol,2005

3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte;Coiffier;Blood,2010

4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;Philip;N Engl J Med,1995

5. Hematopoietic cell transplantation for non-Hodgkin’s lymphoma: yesterday, today, and tomorrow;Appelbaum;J Clin Oncol,2008

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial;British Journal of Haematology;2022-04

2. Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma;Therapeutics and Clinical Risk Management;2021-03

3. Bendamustine/etoposide/pixantrone;Reactions Weekly;2019-05